View Post

Dosing underway in Oncolytics Bio combo study in breast cancer

In Clinical Studies News by Barbara Jacoby

By: Mamta Mayani, SA News Editor From: Oncolytics Biotech (NASDAQ:ONCY) doses first patient in its phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA (OTCPK:MKGAY) and Pfizer (NYSE:PFE). Participants will receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with …